The estimated Net Worth of Jereme M Sylvain is at least $12.2 million dollars as of 9 September 2024. Mr. Sylvain owns over 746 units of Dexcom Inc stock worth over $5,770,241 and over the last 8 years he sold DXCM stock worth over $6,471,383. In addition, he makes $0 as Senior Vice President - Finance et Chief Accounting Officer at Dexcom Inc.
Jereme has made over 25 trades of the Dexcom Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 746 units of DXCM stock worth $51,586 on 9 September 2024.
The largest trade he's ever made was selling 11,661 units of Dexcom Inc stock on 12 March 2024 worth over $1,567,355. On average, Jereme trades about 1,140 units every 79 days since 2017. As of 9 September 2024 he still owns at least 84,274 units of Dexcom Inc stock.
You can see the complete history of Mr. Sylvain stock trades at the bottom of the page.
Jereme M. Sylvain serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. He has served as our Vice President, Finance and Corporate Controller and was promoted to Senior Vice President, Finance and Chief Accounting Officer, effective March 9, 2020. Prior to joining DexCom, Mr. Sylvain held various positions at NuVasive, Inc., including Vice President, Corporate Controller and Chief Accounting Officer from August 2016 to September 2018 and Vice President, Corporate Controller from March 2014 to August 2016. Earlier in his career, he worked for Thermo Fisher Scientific, from February 2014 to March 2014, following its acquisition of Life Technologies Corporation, and Life Technologies and its predecessor, Invitrogen Corporation, from July 2007 to February 2014. Prior to joining Invitrogen, Mr. Sylvain worked for the public accounting firm Ernst & Young LLP. Mr. Sylvain obtained his Certified Public Accounting license after receiving a B.A. in Finance from Arizona State University and a M.S. in Accountancy from the University of Notre Dame.
Jereme Sylvain is 40, he's been the Senior Vice President - Finance et Chief Accounting Officer of Dexcom Inc since 2020. There are 28 older and 1 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Jereme's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff et Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: